Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature

Current Opinion in Hematology

Volumn 17, Issue 2, 2010, Pages 125-132

  Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

KITD816V; Mast cell; Myeloproliferative neoplasm

Indexed keywords

2 CHLOROADENOSINE; ALPHA INTERFERON; BCR ABL PROTEIN; CLADRIBINE; DASATINIB; HYDROXYUREA; IMATINIB; MIDOSTAURIN; NILOTINIB; PREDNISONE;

ALGORITHM; ANEMIA; BONE MARROW SUPPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; GENE; GENE MUTATION; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LIFE EXPECTANCY; MAST CELL LEUKEMIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC MASTOCYTOSIS; TET2 GENE; THROMBOCYTOPENIA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING;

CLADRIBINE; HUMANS; INTERFERON-ALPHA; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TREATMENT OUTCOME;

EID: 76749089140     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283366c59     Document Type: Review

References (60)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
2. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113:5727-5736.
3. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92:1736-1744.
4. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108:2366-2372.
5. Zappulla JP, Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 2005; 202:1635-1641.
6. Ferrao PT, Gonda TJ, Ashman LK. Constitutively active mutant D816VKit induces megakaryocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leuk Res 2003; 27:547-555.
7. Mayerhofer M, Gleixner KV, Hoelbl A, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008; 180:5466-5476.
8. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289-2301.
9. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23:905-911.
10. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23:900-904.
11. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/ MPN and AML. Leukemia 2009; 23:1343-1345.
12. Langemeijer SM, Kuiper RP, BerendsM, et al. Acquired mutations inTET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41:838-842.
13. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979; 3:349-365.
14. Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985; 179:439-461.
15. Sagher F, Even-Paz Z. Mastocytosis and the mast cell. Chicago, Illinois, USA: Year Book Medical Publishers; 1967.
16. Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990; 76:186-193.
17. Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67:345-368.
18. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-625.
19. Valent P, Horny H-P, Li C-Y, et al. Mastocytosis (mast cell disease). In: Jaffe E, et al., editors. WHO classification of tumours, pathology and genetics. Tumours of haematopoetic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 292-302.
20. Pardanani AD, Lim K-H, Lasho TL, et al. Indolent mastocytosis in 159 adults: smoldering but not bone marrow only variant is prognostically significant [abstract #2906]. Blood 2009; 114:1135.
21. Horny HP, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: Swerdlow SH, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: International Agency for Research and Cancer (IARC); 2008. pp. 54-63.
22. Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000; 28:140-147.
23. Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002; 100:661-665.
24. Kim Y, Weiss LM, Chen YY, Pullarkat V. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res 2007; 31:1749-1754.
25. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological nonmast cell lineage diseases: a histo-pathological challenge. J Clin Pathol 2004; 57:604-608.
26. Travis WD, Li CY, Yam LT, et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988; 62:965-972.
27. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009; 114:3769-3772.
28. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11:58-64. (Pubitemid 38021722)
29. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119:1090-1097.
30. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992; 326:619-623.
31. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998; 138:489-495.
32. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28:249-257.
33. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102:4270-4276.
34. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344:307-309.
35. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28:127-131. (Pubitemid 37492938)
36. Pardanani A, Elliott M, ReederT, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362:535-536.
37. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006; 107:345-351.
38. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33:1481-1484.
39. Lim K-H, Pardanani A, Butterfield JH, et al.Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84:790-794.
40. Tanaka A, Konno M, Muto S, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105:2324-2331.
41. Gabillot-Carre M, Lepelletier Y, Humbert M, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 2006; 108:1065-1072.
42. Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109:315-322. (Pubitemid 46053072)
43. Pan J, Quintas-Cardama A, Manshouri T, et al. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci 2007; 98:1223-1225. (Pubitemid 46993542)
44. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22:660-664.
45. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31:686-692.
46. Akin C, FumoG, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103:3222-3225.
47. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007; 87:365-371.
48. Verstovsek S, Akin C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006; 30:1365-1370.
49. von Bubnoff N, Gorantla SH, Kancha RK, et al. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005; 19:1670-1671.
50. Schittenhelm MM, ShiragaS, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-481.
51. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108:286-291.
52. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haema-tologica 2007; 92:1451-1459.
53. Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008; 38:869-873.
54. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 2009; 33:735-741.
55. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14:3906-3915.
56. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic masto-cytosis: four cases. Eur J Haematol 2008; 80:456-458.
57. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106:721-724.
58. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752-759.
59. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106:2865-2870.
60. Gotlib J, George TI, Corless C, et al. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial. ASH Annu Meeting Abstracts 2007; 110:3536.